Annual report pursuant to Section 13 and 15(d)


Cover - USD ($)
$ in Millions
12 Months Ended
Mar. 31, 2022
Jun. 03, 2022
Sep. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Mar. 31, 2022    
Current Fiscal Year End Date --03-31    
Document Transition Report false    
Entity File Number 001-38906    
Entity Registrant Name IMMUNOVANT, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 83-2771572    
Entity Address, Address Line One 320 West 37th Street    
Entity Address, City or Town New York,    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10018    
City Area Code 917    
Local Phone Number 580-3099    
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Trading Symbol IMVT    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Entity Shell Company false    
Entity Public Float     $ 347.0
Entity Common Stock, Shares Outstanding   116,505,412  
Documents Incorporated by Reference
Portions of the registrant’s Proxy Statement for its 2022 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended March 31, 2022.
Entity Central Index Key 0001764013    
Amendment Flag false    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022